FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to neurology, and can be used for treating craniocerebral injury in a subject. Said method comprises administering to a subject a first composition containing a therapeutically effective amount of dexanabinol and a second composition containing a therapeutically effective amount of cannabidiol. Group of inventions also relates to a pharmaceutical composition which contains an effective amount of dexanabinol and an effective amount of cannabidiol.
EFFECT: use of this group of inventions enables effective reduction of neurosensory effects caused by craniocerebral injury by combined therapy with dexanabinol and cannabidiol, providing a positive synergetic effect.
14 cl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| ANESTHETIC COMPOSITION COMPRISING NMDA-ANTAGONIST AND ALPHA-2-ADRENERGIC AGONIST | 2000 |
|
RU2244558C2 |
| COMPOUNDS, METHODS FOR THEIR PREPARING, USING, PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2311418C2 |
| LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
| METHOD FOR TREATMENT OF CEREBROVASCULAR BRAIN DISORDERS (OPTIONS) | 2017 |
|
RU2659674C1 |
| METHOD OF TREATING CRANIOCEREBRAL INJURY AND AGENT FOR IMPLEMENTATION THEREOF | 2023 |
|
RU2826364C1 |
| NEW APPLICATION | 2004 |
|
RU2416426C2 |
| AGENT FOR REDUCTION OF GLUTAMATE-INDUCED APOPTOSIS AND INHIBITION OF NMDA-RECEPTOR, POSSESSING IMMUNOMODULATORY ACTION, FOR TREATING NERVOUS SYSTEM DISORDERS, EFFECTS OF CRANIOCEREBERAL INJURY AND ISCHEMIC AND HEMORRHAGIC STROKE | 2013 |
|
RU2605339C2 |
| XENON AS N-METHYL-D-ASPARTIC ACID ANTAGONIST | 2000 |
|
RU2257902C2 |
| NEUROGENESIS MEDIATED WITH 4-ACYLAMINOPYRIDINE DERIVATIVES | 2007 |
|
RU2451512C2 |
